PDF(Pubmed)
Abstract：
MicroRNAs, short non-protein coding RNAs, are overexpressed in GCTs. Circulating levels of germ cell tumor (GCT)-associated miRNAs, such as miR-371a-3p, can be utilized as efficient and cost-effective alternatives in diagnosing and managing patients presenting with GCTs. This quality of miRNAs has demonstrated favorable performance characteristics as a reliable blood-based biomarker with high diagnostic accuracy compared to current serum tumor markers (STMs), including α-fetoprotein (AFP), beta human chorionic gonadotropin (β-hCG), and lactate dehydrogenase (LDH). The conventional STMs exhibit limited specificity and sensitivity. Potential clinical implications of miRNAs include impact on de-escalating or intensifying treatment, detecting recurrence at earlier stages, and lessening the necessity of cross-sectional imaging or invasive tissue biopsy for non-teratomatous GCTs. Here, we also highlight the outstanding issues that must be addressed prior to clinical implementation. Standards for measuring circulating miRNAs and determining ideal cutoff values are essential for integration into current clinical guidelines.
摘要：
MicroRNAs,短非蛋白质编码RNA，在GCT中过表达。生殖细胞肿瘤（GCT）相关miRNA的循环水平，如miR-371a-3p，可以用作诊断和管理GCT患者的有效和具有成本效益的替代方法。与目前的血清肿瘤标志物（STMs）相比，这种miRNA的质量已证明作为可靠的基于血液的生物标志物具有良好的性能特征，具有高诊断准确性。包括甲胎蛋白（AFP），β人绒毛膜促性腺激素（β-hCG），和乳酸脱氢酶(LDH)。常规STM表现出有限的特异性和灵敏度。miRNA的潜在临床意义包括对降级或强化治疗的影响，检测早期复发，减少非畸胎瘤GCTs横断面成像或侵入性组织活检的必要性。这里,我们还强调了在临床实施之前必须解决的悬而未决的问题。测量循环miRNA和确定理想截断值的标准对于整合到当前临床指南中至关重要。
